Germline mutations in the BRCA1 and BRCA2 genes predispose carriers to breast and ovarian cancer, and there remains a need to identify the specific genomic mechanisms by which cancer evolves in these patients. Here we present a systematic genomic analysis of breast tumors with BRCA1 and BRCA2 mutations, comparing these to common types of sporadic breast tumors.
germline BRCA inactivation 16 .
In this work we combine newly generated sequencing data with previous datasets, and perform an in-depth integrative analysis of genomic and epigenomic data in order to achieve better insights into the mechanism underlying tumor formation in individuals with BRCA gene mutations. Our aim here is to characterize the genomic variation in BRCA-mutated tumors and understand whether and how they are different from common classes of sporadic breast tumors. We present novel results on the differences in point mutation, DNA methylation, and structural variation in BRCA1/2 mutated tumors, and identify specific genes including known tumor suppressors that are frequently damaged by structural variation in these tumors.
Results

BRCA1/2-mutated tumors have a high burden of point mutations.
To compare the point mutation profiles of BRCA-mutated tumors with other breast tumors, we analyzed a published dataset of 560 breast tumors 11 . It includes 36 tumors with inactivating germline or somatic mutations in BRCA1 and 39 with inactivating germline or somatic mutations in BRCA2, as well as 118 triple-negative tumors, 293 ER+ (HER2-) tumors and 71 HER2+ tumors. Both BRCA1-mutated and BRCA2-mutated tumors present a significantly higher number of point mutations than the other classes ( Figure 1) , with BRCA1-mutated tumors having a particularly high number of point mutations. Tumors with somatic BRCA1/2 mutations present similarly high mutation counts to those with germline inactivation.
Differences in mutational signature exposures between BRCA1/2-mutated and sporadic tumors.
Mutational signatures are patterns of point mutations in the genome created by specific mutagenic processes, e.g., a chemical mutagen or a defect in a DNA repair enzyme 17 . If BRCA1/2-mutated tumors evolve via distinct point mutation-causing processes, they may possess unusual mutational signatures. We therefore analyzed whether the BRCA1/2-mutated tumors have a different pattern of mutational signatures from the remaining breast tumors.
A previous study 11 applied a widely used approach 17 for extracting mutational signatures from genomic data to the dataset of 560 breast tumors, resulting in 12 mutational signatures. Notably, the resulting signatures are very dense, and many are also very similar to each other. While some have been linked to known mutational processes in breast cancers, others still have no known etiology 19 . This may be due to the fact that this framework extracts as many signatures as required to improve the fit to the data, without testing whether these signatures perform well at fitting unseen data. This can be expected to result in a high number of signatures that potentially overfit the data. For these reasons, we wished to use a more principled approach that incorporates biological knowledge, as well as statistical methods to prevent overfitting.
We recently developed SparseSignatures 20 , a novel framework to identify mutational signatures.
This method incorporates a background model representing the pattern of mutations caused in the normal course of cell division by DNA replication errors -a signature that we assume is present in all tumors.
The background signature is fixed and additional signatures are discovered while incorporating a LASSO constraint to ensure that the signatures are sparse, producing a more biologically accurate and interpretable solution. SparseSignatures also applies a repeated bi-cross-validation strategy 20 to select the number of signatures. This allows us to avoid overfitting by selecting a number of signatures that not only fit the data used to discover them but are also capable of predicting unseen data points.
We applied this approach to 555 breast tumors (we removed 5 tumors with <1000 mutations as previously described 20 ) . We discovered 8 mutational signatures in addition to the background (Figure 2a , Supplementary Table 1 ). These signatures are statistically strongly supported and most of them are related to known mutagenic mechanisms. Signatures 1 and 2 are associated with defective DNA mismatch repair 21 . Signature 3 is a pattern of elevated TT>GT point mutations, highest in a CTT context. Signature 4 is similar to the previously described 11 'Signature 18', which has recently been associated with DNA damage caused by reactive oxygen species 18 . Signatures 5 and 7 are associated with deregulation of APOBEC cytidine deaminases 19 . Signature 6 is caused by deamination of methylated cytosines at CpG sites into thymine. Finally, Signature 8 is a relatively dense pattern characterized by an elevated rate of C>A, C>G and T>A mutations.
It is notable that despite finding fewer signatures, our solution still provides a better fit to the data (MSE = 364.345) than the previous solution 11 with 12 signatures (MSE = 1118.703). Along with providing a better fit to the data, our discovered signatures are sparser, more clearly differentiated from each other, and lack background noise (Supplementary Table 2 ).
We do not find two signatures described in the previous study -the highly dense, flat 'Signature 3' and 'Signature 8'. While our Signature 8 bears some similarities to the previous 'Signature 3', it is considerably sparser and shows stronger nucleotide preferences, which may be due to our explicit separation of the background signature, thus preventing its being confounded with other signatures. We also do not find a signature similar to the previous 'Signature 30'.
Compared to sporadic tumors, a higher fraction of mutations is attributed to Signature 8 in both BRCA1 and BRCA2-mutated tumors. While the etiology of this signature is uncertain, it is not simply indicative of BRCA mutation as many sporadic triple-negative tumors also have a similarly high contribution by signature 8. In general, the mutational signature profiles of sporadic triple-negative tumors are very close to those of BRCA1/2-mutated tumors, indicating similar underlying mutagenic processes.
BRCA tumors have lower levels of CpG methylation.
SparseSignatures also calculates the exposure values for each signature, i.e. the number of mutations originating from each signature in each patient (Supplementary Table 3 ). On average, the background signature (representing DNA replication errors) contributes more mutations than any other signature. The higher number of point mutations in the BRCA-mutated tumors, compared to sporadic tumors, is reflected in a higher exposure to the background signature, suggesting that these tumors have gone through more cell divisions ( Figure 2b ); in addition, the BRCA-mutated tumors also show higher exposure to all the discovered signatures except for signature 6, which is underrepresented in BRCA-mutated tumors (Figure 2c ). This signature is caused by DNA CpG methylation and subsequent deamination of methylated cytosine to thymine leading to C>T mutation. The ratio of Signature 6 exposure to background signature exposure is significantly lower in both BRCA1 and BRCA2 mutated tumors compared to sporadic tumors (p = 2 x 10 -21 and 1 x 10 -9 respectively; Supplementary Figure 1 ). Taking the background signature exposure as an indicator of cell division, this suggests that BRCA1/2-mutated tumors may have lower CpG methylation.
As DNA methylation data is not available for this dataset, we tested whether DNA methylation is lower in BRCA1/2-mutated tumors in a cohort of 682 breast cancers and 82 normal breast tissue samples from The Cancer Genome Atlas 22 . This dataset included 20 tumors with inactivating germline or somatic mutations in BRCA1 and 13 with inactivating germline or somatic mutations in BRCA2. We found that global CpG methylation levels are indeed significantly reduced in BRCA1-mutated tumors compared to all classes of sporadic tumors as well as normal tissue samples in the same dataset ( Figure 2d ; p(BRCA1-mutated vs. sporadic) = 3 x 10 -4 ; p(BRCA1-mutated vs. normal tissue) = 3 x 10 -5 ). On the other hand, there was no significant difference between BRCA1-mutated and sporadic tumors in the methylation level of the 3081 CpA sites measured on the same platform (Supplementary Figure 2 ). We did not observe a significant difference in methylation levels between BRCA2-mutated and sporadic tumors. However, we note the low number of samples in this analysis.
BRCA1-mutated tumors have elevated tandem duplications and interchromosomal translocations.
We obtained whole-genome sequencing data for 67 of the 560 tumor samples 11 Table 4 describes the selected samples.
We used SvABA 24 to identify somatic indels and structural variants in these tumor genomes.
SvABA is a newly developed indel and structural variant caller that uses genome-wide local assembly to obtain superior sensitivity and specificity to previous methods. After filtering the variant calls (see Methods), we identified a total of 7,234 high-confidence somatic indels and 19,684 high-confidence somatic structural variants in the 81 tumor genomes. We then compared BRCA1/2-mutated tumors against sporadic tumors. We included the 2 tumors with somatic BRCA2 inactivation along with those showing germline BRCA2 inactivation. We found that both BRCA1 and BRCA2-mutated tumors had significantly more indels (p = 1.63 x 10 -5 for BRCA1 and p = 1.37 x 10 -3 for BRCA2) and structural variants (p = 5.12 x 10 -7 for BRCA1 and p = 0.029 for BRCA2) per tumor than the sporadic tumors.
We next examined specific types of variation. Both BRCA1 and BRCA2-mutated tumors have more deletions than sporadic tumors ( Figure 3a ; p(BRCA1/2-mutated vs. sporadic) = 1.96 x 10 -7 ). While most deletions in sporadic tumors are either <5 bp or >10 kb long, BRCA1/2-mutated tumors have a large number of deletions of intermediate size; the size distribution of these deletions is bimodal, with one peak between 5-100 bp and the other between 100 bp-10 kb (Figure 3b ). While the 5-100 bp long deletions mostly lack microhomology at the breakpoints, the majority of the BRCA1/2-mutated samples have short regions of microhomology (1-10 bp) at the breakpoints in >50% of the deletions in the 100 bp-10 kb size range ( Figure 3c ).
On the other hand, we confirmed previous studies 11, 25 showing that BRCA1-mutated tumors have an elevated number of tandem duplications ( Figure 3a ; p(BRCA1 vs. others) = 5.93 x 10 -7 ), predominantly ranging in size from 1-100 kb ( Figure 3b ). Most of the tandem duplications in this size range have short regions of microhomology at the breakpoints (Figure 3c ).
In addition, we observed that the BRCA1-mutated tumors have more interchromosomal translocations than the BRCA2-mutated or sporadic tumors ( Figure 3a ; p(BRCA1-mutated vs. others) = 4.2 x 10 -4 ). To our knowledge this phenomenon has not been described previously. Like the tandem duplications described above, these translocations also tend to have microhomology of 1-10 bp at the breakpoints ( Figure 3c ).
Large copy number alterations in the genome can significantly change genome size. To test whether the elevated numbers of point mutations and structural variants in BRCA1/2-mutated samples are due to biological differences or are accounted for by the availability of more DNA, we identified copy number variants in the genomes of these 81 tumor samples using Control-FREEC 25 . After correcting the size of the genome in each tumor to account for copy number alterations, we find that the BRCA1-mutated samples have larger genomes than BRCA2-mutated or sporadic tumors (Supplementary Figure 3 ). However, normalizing the number of mutations for the actual size of the genome does not affect our results. BRCA1 and BRCA2-mutated tumors still have significantly higher numbers of point mutations and deletions than sporadic tumors, and BRCA1-mutated tumors have significantly higher numbers of tandem duplications and interchromosomal translocations than all other classes of tumors.
Functional regions hit by breakpoints in BRCA-mutated tumors. Since BRCA1/2-mutated tumors
have an elevated number of structural variants, we tested whether these structural variants tend to disrupt functional and regulatory regions of the genome. We found that in BRCA1/2-mutated tumors, the breakpoints for interchromosomal translocations, 1-100 kb duplications and 100 bp-10 kb deletions are all more likely to occur in open chromatin (p = 3.93 x 10 -6 , p = 6.56 x 10 -6 and p = 0.034 respectively). The breakpoints for 1-100 kb tandem duplications and interchromosomal translocations, both of which are elevated in BRCA1-mutated tumors, are also enriched in protein-coding genes (p = 1.73 x 10 -14 and p = 0.014 respectively); the tandem duplication breakpoints are also specifically enriched in exons (p = 1.2 x 10 -3 ). We also found that interchromosomal translocation breakpoints are enriched in TAD boundaries (p = 2.92 x 10 -4 ). Disruption of TAD boundaries has previously been shown to alter gene expression in tumors by modifying 3D contact domains on the chromosome 27 .
We also tested whether the indels and structural variant breakpoints in BRCA1/2-mutated tumors are associated with the local replication timing. The breakpoints for 5-100 bp long deletions (p = 4.33 x 10 -4 ), and for small (<5 bp) indels (p = 9.62 x 10 -16 ) are both enriched in late replicating regions. On the other hand, the breakpoints for 1-100 kb tandem duplications and interchromosomal translocations, both of which are elevated in BRCA1-mutated tumors, are enriched in early replicating regions (p = 4.58 x 10 -19 and p = 3.17 x 10 -11 respectively).
Structural variants disrupt tumor suppressor genes.
We examined the genes that are disrupted by indel and structural variation breakpoints in BRCA1/2-mutated tumors. The genes disrupted by both indels and SVs have significantly (p < 10 -15 for both) higher levels of expression in normal breast tissue, according to RNA-Seq data from GTEx 28 ( Supplementary Figure 4) . Further, the set of genes disrupted by indels and structural variation are both significantly enriched for tumor suppressor genes (p = 1.39 x 10 -5 and p = 4.89 x 10 -10 respectively). We next searched for specific genes enriched for indels or structural variant breakpoints in the BRCA1/2-mutated tumors, using a poisson test. The null model here is that breakpoints are randomly distributed throughout the genome, and we identify protein-coding genes that have significantly more breakpoints than expected from their size. We identified 11 genes enriched for indels/structural variant breakpoints: NME7, KLHL8, EFNA5, PTEN, DHX32, ETV6, RB1, ARGLU1, TP53, P4HB, and RUNX1 ( Table 1 ). After correcting the length of each gene to take into account its copy number in each tumor, 10 of these genes (KLHL8, EFNA5, PTEN, DHX32, ETV6, RB1, ARGLU1, TP53, P4HB, RUNX1) remained significant. 4 of them (PTEN, RB1, TP53 and RUNX1) are known tumor suppressors and have also been identified as potential point mutation driver genes 22 , showing that structural variants in BRCA1/2-mutated tumors hit some of the same drivers that are normally damaged by point mutations in sporadic tumors. However, the remaining 6 genes are not known to be enriched for point mutations in breast cancer, and may therefore represent specific indel/structural variant drivers; of these, ETV6 is known to act as a tumor suppressor in leukemias 29 . Moreover, 4 of these genes (RB1, PTEN, KLHL8, and EFNA5) are also spanned by long deletions in multiple BRCA1/2-mutated samples, representing another mode of inactivation.
Structural variant breakpoints are distributed non-uniformly across the genome. In our set of 46 BRCA1/2-mutated tumor samples, only about 39% of the breakpoints disrupt known genes. While this fraction is significantly higher than expected by chance, we also wanted to test whether there are larger regions of the genome, including non-coding regions, that are enriched for breakpoints. These would include breakpoints for variants that span across whole genes, as well as those that affect gene expression by disrupting regulatory regions of the genome.
We divided the genome into 10-Mb long bins, overlapping by 5 Mb. We then combined all the high-confidence indels and structural variants collected from all the BRCA1/2-mutated tumors. We tested whether these tumors are enriched for indel/structural variant breakpoints in each bin using a poisson test, with the null model being that breakpoints are distributed uniformly across the genome. We found 48 bins that had a Bonferroni-corrected p-value of less than 0.05 (Figure 3d ). All of these regions were disrupted by at least one indel or structural variant in at least 50% of BRCA1/2-mutated tumors. After correcting the number of bases in each bin to account for copy number changes, 28 bins remained significantly enriched (Bonferroni-corrected p<0.05). These bins are located on chromosomes 3, 5, 6, 8, 10, 11, 12, and 18, and several of them overlap with each other. Their coordinates are listed in Supplementary Table 5 .
Validation of interchromosomal translocations using 10X genomics. Our analysis above, as well as previous studies 11.24 , highlight the importance of structural variation in the evolution of BRCA-mutated cancers. However, short-read sequencing is not ideal for accurate detection of large structural variants due to the limited read length. 10X Genomics is a linked-read technology, which uses barcodes to identify short fragments that originate from the same large molecules. Thus it provides long-range information based on short-read sequencing offering improved resolution and detection of structural variants 30 . To validate our findings on structural variants, we sequenced additional DNA from 3 tumors with BRCA1 germline mutations using 10X Genomics sequencing. In addition, we sequenced genomic DNA from 1 BRCA2-mutated tumor and 12 sporadic triple-negative tumors from the same study 22 . We used GROC-SVs 30 to identify structural variants in these genomes.
We reported above a novel finding that BRCA1 mutated tumors have unusually high numbers of interchromosomal translocations. We were able to confirm several of these translocations using 10X sequencing in the 3 BRCA1-mutated samples, providing independent validation of our findings. Further, although the sample size is too small for a statistical test, we observed that these BRCA1-mutated samples had more translocations on average than the sporadic tumors (Supplementary Table 6 ).
Although structural variants are normally classified into simple categories (such as duplications, deletions, and translocations), recent studies have revealed that some tumor genomes also contain a large number of complex structural variants (CSVs) that cannot be explained by a simple end-joining or recombination event 31 . In our short-read data, we observe that 16% of structural variants are accompanied by a short insertion at the breakpoint; the occurrence of such insertions is not significantly different in BRCA1/2-mutated tumors. However, larger CSVs composed of multiple rearrangements cannot be detected by short reads. The use of 10X read clouds and GROC-SVs allows us to resolve larger complex events, since the read clouds span multiple breakpoints.
Using GROC-SVs, we detected two complex structural variants in the sample T65 which has a germline BRCA1 mutation: a complex rearrangement on chromosome 11 ( Supplementary Figure 5a) and a rearrangement involving a translocation between chromosomes 1 and 2 ( Supplementary Figure 5b) . The mechanisms that give rise to such complex variants are still uncertain, but our observations suggest that these may play a role in the evolution of BRCA-mutated tumors. Further studies are required to ascertain whether BRCA-mutated tumors differ from sporadic breast tumors in the number and type of complex structural variants, as has been characterized for simple structural variants.
Discussion
Tumors carrying mutations in the BRCA1 and BRCA2 genes, particularly in BRCA1, have more point mutations than sporadic breast tumors, which is not explained by their larger genome size owing to copy number alterations. If the increased number of mutations in BRCA samples was a function of more cell divisions, we would expect this to be explained by higher exposure to the background signature. We do see higher exposure to the background signature in these tumors, indicating that they have passed through more cell divisions. However, we also see more mutations attributed to other mutagenic processes, particularly Signature 5 (APOBEC dysregulation leading to C>G mutations) and Signature 8, whose etiology is unknown. This indicates that more cell division may not be the only factor contributing to the higher mutational burden of BRCA1/2-mutated tumors, and that other mutagenic processes are also elevated.
Although BRCA1/2-mutated tumors have have a higher exposure to the background signature, they do not have a higher exposure to Signature 6, which represents deamination of methylated cytosines at CpG sites. Under conditions of constant DNA methylation, we would expect the exposure values for these two signatures to be proportional to each other. The disproportionately low contribution of Signature 6 to BRCA1/2-mutated tumors suggests a global reduction in methylation levels, which is confirmed by an analysis of TCGA data for BRCA1 tumors. If true, the reduced methylation could cause dysregulation of gene expression and altered binding of gene regulatory proteins. An altered methylation state is also indicative of dedifferentiation of a tumor, and may be linked to the fact that these tumors have undergone more cell divisions.
It is notable that BRCA1/2-mutated mutated tumors do not appear to possess any unique mutational signatures, suggesting an absence of unique point mutational processes that arise from the BRCA gene mutations. (Even Signature 8, which is elevated in BRCA1/2-mutated tumors, has a high contribution to triple-negative tumors in general.) Instead, BRCA1 and BRCA2 mutated tumors display a clearly distinct profile of structural variants. We confirm previous findings 11, 25 related to tandem duplications and deletions, and also find that BRCA1 mutations are associated with an increased number of interchromosomal translocations, which to our knowledge has not been shown before.
The functional relevance of structural variants in BRCA1/2 mutated tumors is shown by their enrichment in protein-coding genes, particularly genes with high expression in breast tissue. We identified 11 genes that are enriched for indels and structural variant breakpoints in BRCA1/2-mutated tumors; these include well-known tumor suppressors such as TP53 and RB1, showing that in BRCA1/2-mutated tumors, structural variants may carry out the same roles that are more likely to be fulfilled by point mutations in sporadic tumors. We also find additional genes which are candidates for indel/SV-specific driver genes in BRCA1/2 mutated tumors; these frequently damaged genes may have links to the specific biology of tumors with BRCA mutations.
Conclusions
Overall, our study suggests that BRCA1/2-mutated tumors are comparatively more aggressive than sporadic breast cancers because loss of the BRCA pathway(s) causes a perfect storm of mutagenic processes and gene dysregulation: Less DNA methylation is consistent with the propensity to deregulate and dedifferentiate, and the resulting larger numbers of cell divisions cause a greater point mutational burden; other point-mutagenic processes that may be linked to the tissue of origin and occur in sporadic breast tumors are also active (e.g., APOBEC dysregulation); and crucially, loss of double-strand break repair elevates structural variation rates such that there is a greater chance that driver genes that are hard to functionally affect with point mutations are disrupted at a higher rate than in sporadic tumors.
Methods
Preprocessing data for mutational signature extraction. Point mutations occurring in a genome can be divided into 96 categories based on the base being mutated, the base it is mutated into and its two flanking bases. We therefore represent the dataset of 560 patients from Nik-Zainal et al. 11 as a mutation count matrix M of size 560 x 96, where element is the number of mutations belonging to category j in M i,j patient i . As discussed in SparseSignatures 20 , we removed 5 patients with less than 1000 total mutations, giving a final matrix M of size 555 x 96.
Modeling mutational signatures. A mutational signature can be represented by a vector of length 96; s
where each element represents the probability that this mutagenic process generates a s ... s ] s = [ 1 96 s j mutation of category . Since these are probabilities, they sum to 1. j Alexandrov et al. 17 proposed to represent the mutation count matrix as follows:
is the exposure matrix (giving the number of mutations contributed by each α n × K signature to each patient).
is the exposure for the signature in the patient. is the α ij j th i th β K × J signature matrix, where each row represents a signature. is the proportion of mutations in the β ij i th signature that fall into the category. j th SparseSignatures 19 incorporates a null model based on mutation rates in the germline. This is the pattern of mutations that would be expected in the course of normal cell division, and is denoted by a vector of length , leading to the following representation:
where is a vector of exposures, representing the number of mutations contributed by the null α 0 ('background') signature to each patient.
SparseSignatures also includes two other conceptual improvements: (1) a sparsity constraint based on the LASSO on the matrix in order to reduce noise and enhance sparsity and separation of the β discovered signatures; and (2) a bi-cross-validation approach to choose the number of signatures and avoid overfitting. For details we refer to the paper describing SparseSignatures 20 .
Implementation of SparseSignatures.
In our analysis, we repeated the bi-cross-validation procedure 300 times and we considered values of ranging from 3 to 10 and λ ranging from 0.05 to 0.15. In 10X Genomics Sequencing. We selected 6 BRCA1/2-mutated tumor samples and 12 sporadic triple-negative tumor samples 23 for 10X genomic sequencing. The long genomic DNA was isolated from 5-10mg tumor core using Gentra Puregene Tissue Kit following the manufacturer's instructions (Qiagen, Cat. No 158667). Briefly, the small tumor tissue was ground in liquid nitrogen, lysed in Cell Lysis Solution and Proteinase K, and RNA was digested with RNase A. Protein was pelleted and removed by the addition of Protein Precipitation Solution followed by centrifugation. Genomic DNA was precipitated with isopropanol and resuspended in buffer EB. 1.2ng DNA molecules of long fragment were partitioned and barcoded using 10X Genomics Chromium. Each partition had a unique barcode. The barcoded DNA fragments were produced in parallel through emulsion isothermal amplification such that all fragments generated within a partition shared the same barcode. The resulting DNA fragments (Post GEM DNA) from all partitions of the same sample were pooled and recovered. Libraries were constructed following the manufacturer's protocol through End Repairing, A-tailing, Adaptor Ligation and PCR Amplification.
Each library was then sequenced on one lane with a paired-end 150bp run using the Illumina HiSeqX platform to obtain 30x genomic coverage.
Sequencing data analysis. BWA 32 v0.7.12 was used to align short-read sequencing data to the human genome. Longranger 33 v1.3 was used to align 10X genomics data.
Structural variant calling. BAM files were generated as described above, and for the publicly available data, we downloaded BAM files from the ICGC data portal (https://dcc.icgc.org). We ran SvABA on all BAM files using the default parameters 17 .
Variants with length >=50 bp, as well as interchromosomal translocations, were defined as Structural Variants (SVs) while smaller variants were defined as indels. High-confidence SVs and indels were obtained by selecting variants with (1) both breakpoints in chromosomes 1-22 or X (2) 0 supporting reads in the matched normal sample (3) >=10 supporting reads in the tumor sample, at least 2 of which are split reads in the case of SVs (4) QUAL >= 30 and MAPQ of supporting reads >= 30 (5) neither breakpoint in a gap region (6) Both junctions assembled. We also removed variants that were found in more than one tumor sample or unmatched normal sample, as well as variants found in DGV 34 .
For structural variant detection from 10X genomics prepared samples we used GROC-SVs 30 with default settings.
Copy number calling. We used Control-FREEC 26 to call genome-wide copy number for the samples in our cohort. We used the default parameters for the tool. Data on replication timing was obtained from Carithers et al. 36 . Genomic regions were divided into early-replicating, mid-replicating and late-replicating categories such that a third of the genome for which data was provided was included in each category.
Expression levels in normal human breast tissue was obtained from GTex 28 . SparseSignatures with those obtained in a previous study 11 . Supplementary Table 3 . Exposure values (number of mutations attributed to each signature) for each of the 9 signatures, in each of the 560 breast tumors. Supplementary Table 4 . Details of the 81 samples used for structural variant analysis with SvABA. Supplementary Table 5 . Details of 10-Mb genomic bins with significant enrichment of structural variant breakpoints, in the combined genomes of 46 BRCA1/2 mutated tumors. Supplementary Table 6 . Validation of interchromosomal translocations in BRCA1-mutated tumors using 10X genomics.
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